Type 2 hereditary angioedema treated with acute exacerbation with icatibant: A case report

Abstract

Hereditary angioedema (HAE) is a rare autosomal dominant disorder caused by genetic deficiency or decreased function of C1-es terase inhibitor. It is characterized by swelling of subcutaneous and submucosal tissues of the extremities, gastrointestinal tract, and upper airways which can be life-threatening. Thus, early recognition and treatment of the disease are important. Short- and long-term prophylaxes are used to decrease the severity and frequency of attacks. Icatibant is a selective bradykinin B2-receptor antago nist, earlier treatment of acute attacks and hospital admission. The authors present a case of 47-year-old woman who was diag nosed with type II HAE, danazol as a long term. Her symptoms improved dramatically after drug treatment. The unpredictability and recurrence of HAE attacks could have a negative impact on social life and quality of life. This case shows that timely and proper treat ment could improve quality of life and reduce morbidity and mortality. (Allergy Asthma Respir Dis 2021;9:180-183)